Synta Pharmaceuticals Corp. SNTA today announced that the Company will present at the Jefferies 2015 Global Healthcare Conference on Wednesday, June 3, at 11:30 a.m. (ET) in New York.
A live webcast and replay of the presentation will be available on the "Investors" section of the Company's website, www.syntapharma.com.
About Synta Pharmaceuticals
Synta Pharmaceuticals Corp. is an innovative, agile biopharmaceutical company focused on research, development and commercialization of novel oncology medicines that have the potential to change the lives of cancer patients. Synta's lead oncology drug candidate, ganetespib, a novel heat shock protein 90 (Hsp90) inhibitor, is currently being evaluated in several clinical trials including the pivotal GALAXY-2 Phase 3 trial in non-small cell lung cancer. Building on its extensive expertise in the science of Hsp90, Synta also has a novel proprietary Hsp90 inhibitor Drug Conjugate (HDC) small molecule drug development program. IND enabling studies have commenced for the first clinical candidate from the HDC program, STA-12-8666, and preclinical evaluation of additional HDC candidates is ongoing. For more information, please visit www.syntapharma.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20150527006523/en/
Investors:
Synta Pharmaceuticals Corp.
Daniel Cole,
781-541-7250
dcole@syntapharma.com
or
Argot
Partners
Andrea Rabney, 212-600-1494
andrea@argotpartners.com
or
Media:
Argot
Partners
Eliza Schleifstein, 917-763-8106
eliza@argotpartners.com
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.